MORRISTOWN, N.J., March 11 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the U.S. Food and Drug Administration (FDA) approval of ...

Trelstar® (triptorelin pamoate), indicated in Canada for the palliative treatment of hormone dependent advanced prostate cancer, is now available in a six-month dosing option (22.5 mg). The new dosing ...

CORONA, Calif., Nov. 13 Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its New Drug Application (NDA) for a 6-month formulation of ...

Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced today their partnership to launch Trelstar ® ...

MONTREAL and LAUSANNE, Switzerland, Jan. 8, 2020 /PRNewswire/ -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm, a Swiss-based, ...

"This filing reflects Watson's commitment to urology and to making a difference in the lives of men living with prostate cancer," said Paul Bisaro, Watson's President and Chief Executive Officer.

LAUSANNE, Switzerland, Nov. 13 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly ...

LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational ...

MixJect, a drug delivery system, has been approved for use with Watson’s Trelstar Depot and Trelstar LA (triptorelin pamoate injectable suspension). MixJect features a smaller 21-gauge needle, ...

Watson Pharmaceuticals has received FDA approval of Trelstar (triptorelin pamoate for injectable suspension) 22.5 mg, the first and only six-month intramuscular gonadotropin releasing hormone (GnRH) ...

Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees. Debiopharm is in advanced discussion with a potential partner in Canada and is engaged in a bidding ...